? Cancer Therapeutics Program (CTP) The overall goal of this 25-year-old Program at the Abramson Cancer Center (ACC) is to use mechanistic insights emerging from our basic science labs and CCSG Programs to improve cancer therapy for patients with advanced solid tumors. CTP accomplishes this goal through three Specific Aims: 1) Translate mechanistic biologic insights into Phase I trials; 2) Use data from Phase I trials to perform Phase II and Phase III trials to change clinical practice; and 3) Discover and develop innovative biomarkers that enhance safety and efficacy of cancer therapies. This Program is co-led by Program Leaders (PLs) Drs. Ravi Amaravadi and Naomi Haas, both appointed in 2013. Drs. Amaravadi and Haas are NCI-funded researchers who bring highly complementary scientific visions and a notable depth of experience as accomplished translational researchers. CTP encompasses a full range of basic, translational, and clinical research. CTP works closely with leaders of the ACC Community Outreach and Engagement (COE) to understand the cancer burden in the ACC catchment area and ensure that CTP research addresses the major unmet needs in our catchment area. CTP members work on improving cancer therapies for patients with advanced, lethal and often highly symptomatic solid tumors, including lung, prostate and pancreas cancer, as well as melanoma and others. During the current funding period, the PLs aggressively recruited new junior and senior investigators to CTP, reorganized the Program into disease-focused groups, and promoted intra-Programmatic interactions through carefully selected and relevant scientific themes including autophagy, cancer cell metabolism, targeted therapies, and immunotherapy. These efforts resulted in new multi-investigator grants, including NCI Program Project grants and SPORES that include CTP members, new leadership positions in National Groups, and an increase in collaborative publications. Interventional trial accruals were more than 640 per year on average (in CTP alone), representing an increase compared to the prior funding period; 59% of interventional accruals were on investigator-initiated trials. Major accomplishments include validating autophagy as a cancer target, translating basic findings in DNA damage to new therapies in ovarian and pancreatic cancer, determining the pharmacodynamics of PD-1 therapy in patients with earlier stage melanoma, testing novel immunotherapies such as monalizumab, CD40 mAb, and CAR T cells in patients with solid tumors, and advancing circulating DNA as a biomarker of response in lung cancer. The 31 CTP full members and 28 CTP associate members represent six departments from two schools at Penn. CTP members have $14.7M in annual cancer-related research grant funding (direct costs), of which $3.1M is NCI-funded and $4.5M is peer-reviewed. This represents an increase in total funding of $8M (120% increase) since 2015. Our Program has 16 R01- equivalents. There are 540 cancer-related publications from the Program since 2015. Of these, 19% are intra- Programmatic, 38% resulted from inter-Programmatic collaborations, and 74% are multi-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088745
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325

Showing the most recent 10 out of 1047 publications